NCT05854849View on ClinicalTrials.gov

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

PHASE3RecruitingINTERVENTIONAL
Enrollment

244

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2027

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Camrelizumab

200mg, D1, Q3W, iv drip.

DRUG

Gemcitabine

1000mg/m2, Day 1 and Day 8, Q3W, iv drip, maximum 6 cycles.

DRUG

Cisplatin

80 mg/m2, D1, Q3W, iv drip, maximum 6 cycles.

DRUG

Apatinib

250mg, PO, QD

Trial Locations (1)

510060

RECRUITING

Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER